Medical/Pharmaceuticals

Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2025-06-24 22:02 2760

PanBrain Tech Unveils Breakthrough Brain-Computer Interface Device at BEYOND EXPO 2025 in Macau

MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain Tech Co., Ltd. drew widespread attention at the BEYOND International Technology Innovation Expo 2025 inMacau with the debut of its flagship brain-computer interface (BCI) device, thePanBrain ...

2025-06-23 21:00 4381

OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer

PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment ofDimitry S.A. Nuyten, M.D.,...

2025-06-23 19:55 1743

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...

2025-06-23 10:01 2328

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...

2025-06-23 08:03 2136

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for...

2025-06-19 18:08 2466

111, Inc. Announces First Quarter 2025 Unaudited Financial Results

* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY * Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled h...

2025-06-19 15:03 4796

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-101,NCT06375044

2025-06-19 08:37 2923

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI , a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) inJapan has approved AutocathFFR®, the company's non-invasive, AI-driven sof...

2025-06-19 07:00 3377

Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer

Strategic appointments reflect Medison's continued investment in global scale and operational excellence PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison , the creator of a first-of-its-kind unified global commercialization platform that accelerates the...

2025-06-18 22:36 1881

Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program

PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...

2025-06-18 20:00 2614

WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets

SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near...

2025-06-18 08:00 2393

AI-Powered CDSS Enhances Patient Safety with Real-World Data

SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- The growing demand for personalized medicine has accelerated the adoption of Real-World Data (RWD) in healthcare.The Tungs' Taichung MetroHarbor Hospital inTaiwan, in collaboration with AESOP Technology

2025-06-18 00:05 2188

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64Cu-SAR-bisPSMA. * SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 sta...

2025-06-17 21:04 3453

HanchorBio Presents Promising Data on HCB101 Checkpoint Inhibitor Immunotherapy at ASCO

Interim data on the cancer treatment shows robust potential for balancing efficacy and safety TAIPEI and SHANGHAI and SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- Following a successful launch of Phase 2 clinical trials in March, HanchorBio Inc., a pioneer of i...

2025-06-17 18:00 1617

VSA Signs Letter of Intent to Acquire HopeAI, Accelerating Expansion into AI in Life Science

BEIJING, June 17, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (Nasdaq: VSA) (the "Company" or "VSA") today announced that it has entered into a non-binding letter of intent ("LOI") to acquire HopeAI Inc. ("HopeAI"), a leading artificial intelligence company specializing in AI-powered clinica...

2025-06-17 16:30 4383

Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates

-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.  (Clover; HKEX: 02197), a globa...

2025-06-17 12:48 2212

CodeSteri Launches PlaDeo: The World's First Bio-Plasma Powered Deodorant Device

A Breakthrough in Underarm Odor Control and Axillary Bromhidrosis Treatment SEOUL, South Korea, June 16, 2025 /PRNewswire/ -- CodeSteri Inc., a tech-driven startup based at theHanyang University College of Medicine in Seoul , today announced the launch ofPlaDeo, the world's first electronic deodor...

2025-06-17 01:00 1815

HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China

NANJING, China, June 16, 2025 /PRNewswire/ -- HELP Therapeutics, a global leader in regenerative medicine, and China Resources Sanjiu Pharmaceutical Company, one ofChina's largest pharmaceutical companies, have announced a strategic partnership to co-develop and commercialize the investigational ...

2025-06-16 22:40 2822

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

* Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma * Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 * Partnership leverages stra...

2025-06-16 21:03 2378
1 ... 34353637383940 ... 251

Week's Top Stories